PPT-Etanercept Drugbank ID :

DB00005 Half life 102 30 hrs Description Enbrel etanercept is a dimeric fusion protein consisting of the extracellular ligand binding portion of the human 75 kilodalton. Figure1:Schemainterlinkingforthreedatasetsi.e.DrugBank,Sider,Diseasome. Figure2:Resourcesfromthreedierentdatasetsarefusedattheinstancelevelinordertoexploitin-formationwhicharespreadacrossdiversedatas Figure1:Schemainterlinkingforthreedatasetsi.e.DrugBank,Sider,Diseasome. Figure2:Resourcesfromthreedierentdatasetsarefusedattheinstancelevelinordertoexploitin-formationwhicharespreadacrossdiversedatas DB09052 . Description. . :. Blinatumomab. is a . BiTE. -class (bi-specific T-cell engagers) constructed monoclonal antibody indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). . : . DB00053. . Protein chemical . formula . : C. 2532. H. 3854. N. 672. O. 711. S. 16. Protein . average . weight :. 55597.4000. Half-life. . : . 3.6-10.4 min. . Description. . Human Beta-. glucocerebrosidase. Introduction/Overview . PLANETRA Extension Study: . ACR50 Response Rate. Etanercept vs SB4 (Etanercept Biosimilar): ACR20 Response Rates. Typical Study Design for Biosimilar Switching Studies in Rheumatology. Toxins . Biol. 445. Introduction. I had always heard that dogs were “allergic” to chocolate. I wanted to find . . 1. if this was true, and. . 2. what substance in chocolate could be responsible for this. . Update ArticleBiologics in Rheumatoid ArthritisP K Sharma D Hota P PandhiAbstractRheumatoid arthritis RA is a chronic progressive disease of the joints associated with significant morbiditydeformity a DB00002 . Protein Chemical formula : . C. 6484. H. 10042. N. 1732. O. 2023. S. 36. . Protein Average . wt. . : . 145781.6 . Half life : . Approximately : . 114 hrs . Description. :. . Erbitux. is a targeted therapy.  It is classified as a "monoclonal antibody" and "signal transduction inhibitor" by binding to epidermal growth factor receptors (EGFR).. DB00020 . Protein chemical . formula : . C. 639. H. 1006. N. 168. O. 196. S. 8. Protein . average . weight : . 14434.5000. Description. . :. Sargramostim. is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein. . ID . : . DB00019 . Protein chemical . formula : . C. 845. H. 1343. N. 223. O. 243. S. 9. Protein . average . weight : . 18802.8000. Half life : . 15-80 hrs . Description. . :. . PEGylated. (at N terminus) form of human G-CSF (Granulocyte colony stimulating factor), 175 residues, produced from E. coli via bacterial fermentation. . 1. DRUG NAMES. Chemical name. Development name used internally. Biologic drugs too complex to use chemical name. Non-proprietary name (generic name). Combination name for some combination drugs. Proprietary name (brand name). DB00021 . Protein chemical . formula . : C. 130. H. 219. N. 43. O. 42. Protein . average . weight : . 3056.4000. Chemical name : . H-His-Ser-Asp-. Gly. -. Thr. -. Phe. -. Thr. -Ser-. Glu. -. Leu. -Ser-. Immunosuppressive Agents . RILONACEPT . . DESCRIPTION. INDICATION. Rilonacept. is a . dimeric. fusion protein consisting of portions of IL-1R and the IL-1R accessory
 protein linked to the . DB09302. Description. :. Alirocumab. is a biopharmaceutical drug approved by the FDA in July 2015 as a second line treatment for high cholesterol for adults whose LDL-cholesterol (LDL-C) is not controlled by diet and statin treatment. It is a human monoclonal antibody administered by subcutaneous injection that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood.